Billionaire investors increase stakes in Viking Therapeutics, a pre-revenue biopharma firm developing weight-loss drugs.
Billionaire investors Jeff Yass and Israel Englander are increasing their stakes in Viking Therapeutics, a biopharma firm developing weight management drugs. Its candidate VK2735, a dual GLP-1 and GIP receptor agonist, showed promising weight loss results in trials. While planning phase 3 trials, the company also explores VK2809 for liver conditions. However, with no approved products yet, the stock poses risks and is suited for high-risk investors.
September 07, 2024
3 Articles